CLL Society Dr. Koffman's ASCO 2020 "Top 12" P... - CLL Support

CLL Support

22,467 members38,605 posts

CLL Society Dr. Koffman's ASCO 2020 "Top 12" Picks #s 12, 11, 10

bkoffman profile image
bkoffmanCLL CURE Hero
6 Replies

Dr. Koffman’s ASCO 2020 “Top 12” Picks

The 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) was held virtually in May. While ASCO remains more focused on the latest research in solid tumors, there were several worthwhile abstracts related to CLL. Dr. Koffman takes us through his “Top 12” abstracts in short videos with accompanying text. Here are numbers 12, 11, and 10.

ASCO 2020 Top 12

#12 The shift in therapies for the treatment of CLL patients in the US Veterans Health Administration

cllsociety.org/2020/06/asco...

#11 Clinical activity of anti-ROR1 antibody cirmtuzumab in combination with ibrutinib

tcllsociety.org/2020/06/asco...

#10 Initial results of MRD-driven, time-limited therapy with zanubrutinib, obinutuzumab and venetoclax cllsociety.org/2020/06/asco...

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
6 Replies
Smakwater profile image
Smakwater

bkoffman,

Wonderful how you can provide all of this complex information from scores of intense studies to this audience in such a clear and concise way that is easily to understand.

In regard to ROR1, I would like to nominate Dr. Thomas Kipps to receive the nickname "RORY".

JM

bkoffman profile image
bkoffmanCLL CURE Hero in reply to Smakwater

Thanks. ROR1 seems specific enough but is it robust enough of a target.

Smakwater profile image
Smakwater in reply to bkoffman

It seems the more that is discovered, the more there is known for possible targets and resistance. It would exciting if the trigger source could be discovered and overcome. E.g a code in the DNA.

I recall watching a hematologic symposium where they were discussing how they were customizing NK cells to attack specific targets by adding programmed receptors. These cells were instructed for apoptosis when they ran out of target cells.

Fascinating, but far beyond my thought capability.

Smakwater profile image
Smakwater in reply to bkoffman

Below is a link to the conversation about cell programming (CAR specific).

For those who may be interested, the conversation begins at about 59 min.

I believe that Jackie originally posted this about 9 months ago.

Very interesting and informative.

youtu.be/AoHJbbAVNk8

Smakwater profile image
Smakwater in reply to bkoffman

Although I did not perceive it to be stated in the discussion - ref: Bloodwise video presentation.

I suspect that the programmed targeting cell receptors mentioned are actually chimeric antigen receptors.

bkoffman profile image
bkoffmanCLL CURE Hero in reply to Smakwater

Not sure, but makes sense. I don't think that I have seen this video.

You may also like...

End of suspense! Here is Dr. Koffman's ASCO 2020 \"Top Pick\" #1!

leukemia (CLL)....

Dr. Neil Kay: CLL Society Webinar, Just Diagnosed: What Do I Need to Know?

utm_source=April+7%2C+2020&utm_campaign=April+7%2C+2020+Alert&utm_medium=email. Long after Covid-19...

Tuesday! Nov. 17th CLL Society Webinar \"The Future of CAR-T Therapy: Can CAR-T Cure CLL?”

10%2C+2020&utm_campaign=November+10%2C+2020+Alert&utm_medium=email

CLL Society/ CAR-T! Read the story of Dr. Brian Koffman's 3 years of durable remission post-CAR-T!

three years of durable remission here....

Understanding the CLL micro-environment may ultimately lead us to better control of the disease.

oduction/?utm_source=April+21%2C+2020&utm_campaign=April+21%2C+2020+Alert&utm_medium=email Hope this